Qfitlia (fitusiran) — United Healthcare
Hemophilia B with inhibitors
Initial criteria
- Diagnosis of hemophilia B
- Patient has developed high-titer factor IX inhibitors (≥ 5 Bethesda units [BU])
- age ≥ 12 years
- Prescribed for the prevention of bleeding episodes (routine prophylaxis)
Reauthorization criteria
- Documentation of positive clinical response to Qfitlia therapy
Approval duration
12 months